Search
Oxyphenisatin
go.drugbank.com/drugs/DB04823ApprovedWithdrawnA laxative that undergoes enterohepatic circulation. It may cause jaundice.
Lysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalMany emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. … Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder
Methaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnMethaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. … Its use peaked in the early 1970s as a hypnotic, sedative, and muscle relaxant commonly used for insomnia.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalIt is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnPharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.
Tetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Synonyms: 1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizineIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. … Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.